Literature DB >> 26574792

Defining and recognising locally advanced basal cell carcinoma.

Jean Michel Amici1, Maxime Battistella1, Marie Beylot-Barry1, Anne Chatellier1, Sophie Dalac-Ra1, Brigitte Dreno1, Claire Falandry1, Nicolas Froget1, Damien Giacchero1, Jean Jacques Grob1, Pierre Guerreschir1, Marie-Thérèse Leccia1, Olivier Malard1, Laurent Mortier1, Emilie Routier1, Andreea Stefan1, Dinu Stefan1, Pierre-Emmanuel Stoebner1, Nicole Basset-Seguin2.   

Abstract

BACKGROUND: Rarely, basal cell carcinomas (BCCs) have the potential to become extensively invasive and destructive, a phenomenon that has led to the term "locally advanced BCC" (laBCC). We identified and described the diverse settings that could be considered "locally advanced".
METHODS: The panel of experts included oncodermatologists, dermatological and maxillofacial surgeons, pathologists, radiotherapists and geriatricians. During a 1-day workshop session, an interactive flow/sequence of questions and inputs was debated.
RESULTS: Discussion of nine cases permitted us to approach consensus concerning what constitutes laBCC. The expert panel retained three major components for the complete assessment of laBCC cases: factors of complexity related to the tumour itself, factors related to the operability and the technical procedure, and factors related to the patient. Competing risks of death should be precisely identified. To ensure homogeneous multidisciplinary team (MDT) decisions in different clinical settings, the panel aimed to develop a practical tool based on the three components.
CONCLUSION: The grid presented is not a definitive tool, but rather, it is a method for analysing the complexity of laBCC.

Entities:  

Keywords:  basal cell carcinoma; definition; locally advanced

Mesh:

Year:  2015        PMID: 26574792     DOI: 10.1684/ejd.2015.2641

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  3 in total

1.  Clinical and Histopathologic Characteristics of Metastatic and Locally Advanced Cutaneous Basal Cell Carcinomas.

Authors:  Laura X Baker; Erica Grilletta; Jeffrey P Zwerner; Alan S Boyd; Lee Wheless
Journal:  Am J Dermatopathol       Date:  2021-12-01       Impact factor: 1.533

2.  Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.

Authors:  R Dummer; A Guminksi; R Gutzmer; J T Lear; K D Lewis; A L S Chang; P Combemale; L Dirix; M Kaatz; R Kudchadkar; C Loquai; R Plummer; H-J Schulze; A J Stratigos; U Trefzer; N Squittieri; M R Migden
Journal:  Br J Dermatol       Date:  2019-12-08       Impact factor: 9.302

Review 3.  Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma.

Authors:  Neha Gupta; Emily S Ruiz
Journal:  Drug Des Devel Ther       Date:  2022-01-14       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.